PDE1-IN-6

Cat. No.:	HY-163406
CAS No.:	2877017-16-6
Molecular Formula:	$C_{24}H_{26}F_2N_6O$
Molecular Weight:	452.5
Target:	Apoptosis; Phosphatase
Pathway:	Apoptosis; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

PDE1-IN-6 (compound 6c) is a selectivity PDE1 inhibitor with the IC_{50} of 7.5 nM. PDE1-IN-6 significantly inhibits the proliferation and induced cell apoptosis in Acute myelogenous leukemia cells[1].

In Vitro

PDE1-IN-6 (compound 6c) (10 and 20 μM, 48 h) induces the apoptosis of U937 and ML-1 cells[1].
PDE1-IN-6 (10 and 20 μM, 48 h) decreases the expression of caspase-3, 7, 9, PARP, Bcl-2 and Bcl-xl protein, and increases their cleaved caspase-3, 7, 9 in U937 and ML-1 cells[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1]

Cell Line:	U937 and ML-1 cells
Concentration:	10, 20 μM
Incubation Time:	48 h
Result:	Induced the apoptosis of U937 and ML-1 cells.

Western Blot Analysis[1]

Cell Line:	U937 and ML-1 cells
Concentration:	10, 20 μM
Incubation Time:	48 h
Result:	Decreased the expression of caspase-3, 7, 9, PARP, Bcl-2 and Bcl-xl protein, and increased their cleaved caspase-3, 7, 9.

REFERENCES

[1]. Le ML, et al. Discovery of novel selective phosphodiesterase□1 inhibitors for the treatment of acute myelogenous leukemia. Bioorg Chem. 2024;144:107114.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA